title: [Two long-term survival cases of unresectable intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy and radiation therapy].
abstract: The prognosis for patients with unresectable intrahepatic cholangiocarcinoma(ICC) is extremely poor. Case 1 was a 65- year-old woman who had an ICC of 9 cm in diameter (mass-forming type) in the right lobe with portal trunk invasion. She was treated with hepatic arterial infusion chemotherapy[cisplatin(CDDP)/5-fluorouracil(5-FU)/l-leucovorin(l-LV)] and radiation therapy (total dose, 50 Gy). After 6 months, abdominal computed tomography (CT) revealed that the tumor had regressed. She survived for 7 years without recurrence of the ICC; subsequently, she died of peritoneal cancer. Case 2 was a 59-year-old woman who had an ICC of 8 cm in diameter (mass-forming type) in the left lobe with lymph node metastasis in the hepatoduodenal ligament; the right hepatic artery was involved by the metastatic lymph nodes. She was treated with hepatic arterial infusion chemotherapy(CDDP/5-FU/l-LV) and radiation therapy(total dose, 30 Gy). After 10 months, abdominal CT revealed that the tumor had disappeared, but paraaortic and mediastinal lymph node metastases were detected. She was therefore treated with systemic chemotherapy. Treatment with systematic chemotherapy enabled her to survive for over 5 years with a good performance status.
authors.affiliation: Dept. of Hepato-Biliary-Pancreatic Surgery and Gastroenterological Surgery, Osaka City General Hospital, Japan.
authors.forename: Hisateru
authors.initials: H
authors.lastname: Komatsu
authors.forename: Akishige
authors.initials: A
authors.lastname: Kanazawa
authors.forename: Tadashi
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Sadatoshi
authors.initials: S
authors.lastname: Shimizu
authors.forename: Akira
authors.initials: A
authors.lastname: Ishikawa
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Mori
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Nakajima
authors.forename: Go
authors.initials: G
authors.lastname: Ohira
authors.forename: Shintaro
authors.initials: S
authors.lastname: Kodai
authors.forename: Junya
authors.initials: J
authors.lastname: Morimoto
authors.forename: Sadaaki
authors.initials: S
authors.lastname: Yamazoe
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yamamoto
authors.forename: Toru
authors.initials: T
authors.lastname: Inoue
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Yukio
authors.initials: Y
authors.lastname: Nishiguchi
authors.forename: Teruyuki
authors.initials: T
authors.lastname: Ikehara
authors.forename: Koichi
authors.initials: K
authors.lastname: Taira
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Horii
authors.forename: Osamu
authors.initials: O
authors.lastname: Yamazaki
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms; D001653:Bile Ducts, Intrahepatic; D059248:Chemoradiotherapy; D018281:Cholangiocarcinoma / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D013997:Time Factors
chemical_list: D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil